Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators. Vaduganathan M, et al. Among authors: cannon cp. J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068. Epub 2016 Mar 21. J Am Coll Cardiol. 2016. PMID: 27012778 Free article. Clinical Trial.
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL; COGENT Investigators. Vaduganathan M, et al. Among authors: cannon cp. Am J Med. 2016 Sep;129(9):1002-5. doi: 10.1016/j.amjmed.2016.03.042. Epub 2016 Apr 30. Am J Med. 2016. PMID: 27143321 Clinical Trial.
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS. Cannon CP, et al. Am J Cardiol. 2019 Apr 15;123(8):1202-1207. doi: 10.1016/j.amjcard.2019.01.028. Epub 2019 Jan 25. Am J Cardiol. 2019. PMID: 30736965 Free article.
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Hohnloser SH, et al. Among authors: cannon cp. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050. JACC Cardiovasc Interv. 2019. PMID: 31439336 Free article. Clinical Trial.
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Ten Berg JM, et al. Among authors: cannon cp. JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039. JACC Cardiovasc Interv. 2019. PMID: 31806214 Free article. Clinical Trial.
1,011 results